Gene therapy company Immusoft takes in $3 mln
Seattle-based gene therapy company Immusoft has closed the first part of its Series B funding round at $3 million. The lead investor was 600 Mile Challenge Fund. In addition to this transaction, Sean Ainsworth, who founded and led RetroSense Therapeutics, is Immusoft's new CEO and board chairman. Also, Dr. Anthony Sun has been added to the board.
5 January 2018•1 min read
